ACTIVE

APOTHEEK SUYKERBUYK

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result49,6 k €-36,0 %over 1 year

Gross margin443,4 k €-1,6 %over 1 year

Equity700,3 k €-42,3 %over 1 year

Workforce4,3 ETP+4,9 %over 1 year

Identity

Source · BCE/KBO

APOTHEEK SUYKERBUYK is a Private limited company incorporated in 1992. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Antwerpen. It employs on average 4,3 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0448.564.919
Incorporation: 30/10/1992
Legal form: Private limited company
Registered office: Monnikenhofstraat 105
2040 Antwerpen · FlandreSee on map
Contributed capital: 37 600,00 €
Latest accounts: 31/12/2025
Average workforce: 4,3 ETP

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 20 filings

Trend over 20 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	443,4 k €	-1.6%	450,8 k €	-1.3%	456,6 k €	+7.6%	424,4 k €	+82.2%	232,9 k €
EBITDA	101,8 k €	-24.6%	134,9 k €	-5.5%	142,8 k €	+3.1%	138,5 k €	+472%	-37,2 k €
Operating result	75 k €	-30.3%	107,6 k €	-4.9%	113,1 k €	+17.9%	96 k €	+195%	-101,3 k €
Net result	49,6 k €	-36.0%	77,5 k €	-11.0%	87,1 k €	+1.3%	86 k €	+193%	-92,4 k €
Balance sheet
Equity	700,3 k €	-42.3%	1,2 M €	-0.0%	1,2 M €	+7.7%	1,1 M €	+8.3%	1 M €
Total assets	1,5 M €	-23.1%	2 M €	+3.5%	1,9 M €	-3.1%	2 M €	+4.4%	1,9 M €
Cash	116,3 k €	+57.4%	73,9 k €	-81.1%	391,2 k €	-2.0%	399,1 k €	+102%	197,1 k €
Debts	805,4 k €	+8.2%	744,2 k €	+10.1%	676,2 k €	-18.0%	824,6 k €	-0.4%	827,6 k €
Other
Workforce	4,3 ETP	+4.9%	4,1 ETP	-4.7%	4,3 ETP	+4.9%	4,1 ETP	+2.5%	4,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 5 ended

Active mandates

ANTWERP PHARMACIES

Director · 0700.733.344

Represented by Joris MEES

Active

Ended mandates

Gerwin Vandepitte

Manager · since 09 juillet 2018

Ended

GEVAC-INVEST BVBA

Manager · since 01 juillet 2004 · until 09 juillet 2018 · 0865.292.854

Represented by Gerwin Vandepitte

Ended

GEVAC-INVEST BVBA

Manager · since 01 juillet 2004 · 0865.292.854

Represented by Gerwin VANDEPITTE

Ended

ANTWERP PHARMACIES

Director · 0700.733.344

Represented by Joris Mees

Ended

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	02/07/2026	23/06/2025	18/06/2024	05/07/2023	17/06/2022	14/06/2021
General meeting	12/06/2026	13/06/2025	14/06/2024	09/06/2023	10/06/2022	11/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 20 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	12/06/2026	02/07/2026	Dutch	PDF
Abridged model	31/12/2024	13/06/2025	23/06/2025	Dutch	PDF
Abridged model	31/12/2023	14/06/2024	18/06/2024	Dutch	PDF
Abridged model	31/12/2022	09/06/2023	05/07/2023	Dutch	PDF
Abridged model	31/12/2021	10/06/2022	17/06/2022	Dutch	PDF
Abridged model	31/12/2020	11/06/2021	14/06/2021	Dutch	PDF
Abridged model	31/12/2019	12/06/2020	02/07/2020	Dutch	PDF
Abridged model	31/12/2018	14/06/2019	17/06/2019	Dutch	PDF
Abridged model	31/12/2017	16/04/2018	09/05/2018	Dutch	PDF
Abridged model	31/12/2016	09/06/2017	22/06/2017	Dutch	PDF
Abridged model	31/12/2015	30/06/2016	27/07/2016	Dutch	PDF
Abridged model	31/12/2014	30/06/2015	30/07/2015	Dutch	PDF
Abridged model	31/12/2013	13/06/2014	19/06/2014	Dutch	PDF
Abridged model	31/12/2012	14/06/2013	26/06/2013	Dutch	PDF
Abridged model	31/12/2011	30/06/2012	24/07/2012	Dutch	PDF
Abridged model	31/12/2010	10/06/2011	08/07/2011	Dutch	PDF
Abridged model	31/12/2009	11/06/2010	05/07/2010	Dutch	PDF
Abridged model	31/12/2008	30/06/2009	31/07/2009	Dutch	PDF
Abridged model	31/12/2007	13/06/2008	10/07/2008	Dutch	PDF
Abridged model	31/12/2006	29/06/2007	27/07/2007	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 5 ended

Active mandates

ANTWERP PHARMACIES

Director · 0700.733.344

Represented by Joris MEES

Active

Ended mandates

Gerwin Vandepitte

Manager · since 09 juillet 2018

Ended

GEVAC-INVEST BVBA

Manager · since 01 juillet 2004 · until 09 juillet 2018 · 0865.292.854

Represented by Gerwin Vandepitte

Ended

GEVAC-INVEST BVBA

Manager · since 01 juillet 2004 · 0865.292.854

Represented by Gerwin VANDEPITTE

Ended

ANTWERP PHARMACIES

Director · 0700.733.344

Represented by Joris Mees

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Other29/06/2021
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - BENAMING - DOEL
PDF
Mandates19/10/2020
ONTSLAGEN - BENOEMINGEN
PDF
Mandates16/09/2019
ONTSLAGEN - BENOEMINGEN
PDF
Mandates13/09/2018
ONTSLAGEN - BENOEMINGEN
PDF
Restructuring10/08/2018
RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
PDF
Restructuring05/06/2018
RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
PDF
Mandates05/08/2004
KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2025
Annual accounts 202549,6 k €↓
2024
Annual accounts 202477,5 k €↓
2023
Annual accounts 202387,1 k €↑
2023
Name changeAPOTHEEK SUYKERBUYK
2022
Annual accounts 202286 k €↑
2021
Annual accounts 2021-92,4 k €↓
2021
Name changeSuykerbuyk Apotheek
2020
Annual accounts 2020-81 k €↓
2019
Annual accounts 2019178,9 k €↓
2018
Annual accounts 2018336,6 k €↑
2017
Annual accounts 2017228,4 k €↓
2016
Annual accounts 2016240,7 k €↑
2015
Annual accounts 2015221 k €↑
2014
Annual accounts 2014212,2 k €↓
2013
Annual accounts 2013257,3 k €↑
2012
Annual accounts 2012239,5 k €↓
2011
Annual accounts 2011353,4 k €↑
2010
Annual accounts 2010212,4 k €↓
2009
Annual accounts 2009214,4 k €↑
2008
Annual accounts 2008190 k €↓
2007
Annual accounts 2007218,4 k €↑
2006
Annual accounts 2006179 k €
2006
Name changeAPOTEEK SUYKERBUYK
30/10/1992
IncorporationPrivate limited company

APOTHEEK SUYKERBUYK

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline